Loading...
XWAR
BIO
Market cap97mUSD
Jul 15, Last price  
4.18PLN
1D
0.24%
1Q
14.84%
Jan 2017
-48.84%
IPO
-88.50%
Name

Bioton SA

Chart & Performance

D1W1MN
P/E
—
P/S
1.73
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
0.56%
Revenues
208m
+14.38%
151,586,000215,479,000270,942,000293,517,000286,228,000378,595,000288,984,000406,303,000340,358,000377,303,000404,408,000277,613,000361,649,000241,166,000202,032,000221,788,000163,034,000233,159,000181,636,000207,763,000
Net income
-16m
L
34,627,00092,698,00026,572,000-223,033,000-599,878,000110,726,000-83,936,00037,837,000-6,443,0003,678,000-522,855,000-28,567,000-7,266,00026,266,000-126,693,00033,920,0002,882,0001,421,0002,275,000-15,658,000
CFO
36m
-8.32%
7,127,000-10,763,000-530,00037,745,000-80,222,00027,170,000-22,200,000144,796,00079,963,00041,874,00024,023,00023,146,00017,503,00027,880,00046,707,00041,949,0005,522,00056,082,00039,625,00036,330,000

Profile

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities. The company was founded in 1989 and is based in Ozarów Mazowiecki, Poland.
URL
https://bioton.com/
IPO date
Mar 16, 2005
Employees
355
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
207,763
14.38%
181,636
-22.10%
233,159
43.01%
Cost of revenue
214,164
185,745
208,086
Unusual Expense (Income)
NOPBT
(6,401)
(4,109)
25,073
NOPBT Margin
10.75%
Operating Taxes
3,778
4,959
3,531
Tax Rate
14.08%
NOPAT
(10,179)
(9,068)
21,542
Net income
(15,658)
-788.26%
2,275
60.10%
1,421
-50.69%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
42,870
56,016
57,737
Long-term debt
33,308
26,816
32,925
Deferred revenue
33,877
29,814
32,745
Other long-term liabilities
5,058
3,421
(20,686)
Net debt
69,215
78,949
79,966
Cash flow
Cash from operating activities
36,330
39,625
56,082
CAPEX
(11,613)
(44,166)
(29,578)
Cash from investing activities
(11,613)
(36,952)
(29,100)
Cash from financing activities
(21,637)
(8,129)
(26,499)
FCF
(9,486)
(13,471)
56,013
Balance
Cash
6,963
3,883
9,339
Long term investments
1,357
Excess cash
Stockholders' equity
620,100
549,227
635,404
Invested Capital
686,051
708,286
691,302
ROIC
2.95%
ROCE
3.46%
EV
Common stock shares outstanding
85,864
85,864
85,864
Price
2.89
-19.05%
3.57
5.93%
3.37
-19.47%
Market cap
248,148
-19.05%
306,535
5.93%
289,362
-19.47%
EV
317,363
385,484
455,803
EBITDA
29,886
30,875
59,476
EV/EBITDA
10.62
12.49
7.66
Interest
8,159
8,427
7,858
Interest/NOPBT
31.34%